Chapter. 13

Fructose and the Heart

Metabolic Risk Factors in the 21st Century have replaced cigarette smoking as the Leading Drivers of Cardiovascular Mortality Worldwide”

The consequences of ignoring the role of fructose and fifty years of diversion into the study of fats allowed the industries behind High Fructose Corn Syrup to spread this mutant sugar all over the United States and now all over the planet.
As we look back, it has been obvious all along, but very well suppressed by Big Food.

13.1: Introduction — The Great Misdirection in Cardiovascular Disease

The global epidemic of cardiovascular disease is not a mystery. It is the outcome of a decades-long misdirection—a failure to identify fructose as a core driver of vascular injury, while the medical establishment chased cholesterol and fat. This redirection wasn’t random. It was the result of industry influence, institutional inertia, and a tendency in public health to follow what’s easy to measure, rather than what causes harm.

Early Warnings from an Unexpected Source

Long before LDL was measured, before dietary fat was vilified, the warning signs of a cardio-metabolic crisis were already visible—not in medical journals, but in actuarial tables. In the 1920s and 1930s, life insurance companies like Metropolitan Life began collecting large datasets linking overweight and premature death. They weren’t trying to save lives. They were trying to price risk.

In 1943, statistician Louis Dublin and epidemiologist Donald Armstrong published data from thousands of insured individuals. Their conclusion: excess body weight predicted early cardiovascular death—long before doctors were willing to say it out loud. In men aged 20–29, being just 25–34 pounds overweight increased mortality by 34%. Those who exceeded 135% of ideal weight faced a 63% increase.

At the time, sugar was already under suspicion, though biochemistry lacked the language to distinguish between glucose and fructose. We now know: it is the fructose half of the sucrose molecule—and the isolated form in high-fructose corn syrup (HFCS)—that behaves like a vascular toxin.

What Wartime Famine Taught Us

In 1947, Dr. S.L. Wilens published autopsy data comparing arterial pathology in patients from New York and post-war Costa Rica. His findings: individuals who experienced caloric deprivation during wartime had significantly less atherosclerosis than their overfed counterparts. Among 45–54 year-olds, only 6.7% of undernourished patients had advanced disease, compared to 20% of the obese. In older adults, the difference was even greater.
Other tragic “experiments” during World War II confirmed the trend. In the Netherlands and parts of China, where sugar and refined foods became scarce due to rationing, rates of cardiovascular disease plummeted. After the war, as sugar returned, so did heart attacks.
These weren’t anecdotes. They were epidemiological sirens—ignored or reframed.
Despite decades of actuarial, autopsy, and international famine data, cardiology chose a different villain. The focus shifted to dietary fat and cholesterol, and fructose slipped through—unlabeled, unregulated, and eventually embedded in the food supply under government subsidies and false reassurances.


13.2: Fat vs. Sugar (1950s–1970s)

A Presidential Heart Attack, A Nutritional Detour
In 1955, President Dwight D. Eisenhower suffered a heart attack. His health crisis made headlines across the world and catalyzed a shift in public consciousness: heart disease was no longer a rare affliction. It had become a national emergency.
Eisenhower’s cardiologist, Dr. Paul Dudley White, was a pioneer of preventive cardiology. But like many of his contemporaries, he was heavily influenced by the cholesterol hypothesis—the belief that dietary fat and cholesterol were the primary causes of atherosclerosis. As a result, the President was placed on a strict fat-restricted diet, and the public followed suit.
Butter, eggs, and red meat became nutritional villains. Newspapers published the President’s meals, and Americans internalized a clear message: fat was the enemy.
Yet Eisenhower’s heart disease progressed relentlessly. He suffered recurrent myocardial infarctions and ultimately died of congestive heart failure in 1969. The dietary experiment had failed—but the narrative had already taken hold. Fat was blamed, and sugar was ignored.

Yudkin vs. Keys — The Silenced Debate
While the United States chased dietary fat, a dissenting voice emerged in Britain.
Dr. John Yudkin, a professor of nutrition at Queen Elizabeth College, had been studying sugar since the 1950s. His laboratory findings were alarming: animals fed high-sugar diets developed obesity, insulin resistance, dyslipidemia, and even aggressive behavior. His epidemiological research linked sugar consumption with rising rates of diabetes and cardiovascular disease.
In 1972, Yudkin published Sweet and Dangerous—later reissued as Pure, White, and Deadly. In it, he proposed that sugar—not fat—was the dietary culprit behind heart disease. His conclusions were evidence-based, but they were politically toxic.
Yudkin’s warnings clashed with the dominant narrative promoted by Ancel Keys, whose Seven Countries Study laid the foundation for the diet-heart hypothesis. Keys dismissed Yudkin publicly and aggressively. The sugar industry and academic institutions aligned behind Keys’ fat-centric model, and paid the Harvard researchers to publish that corrupt article in the New England Journal of Medicine. Yudkin was discredited.

The Consequences of a Narrative
As Yudkin was pushed to the margins, a nutritional revolution took hold:
• Saturated fats were reduced or removed
• Low-fat products became the standard
• Sugars and emulsified starches filled the flavor gap
• Food labels focused on fat grams and cholesterol, while sugar was overlooked
The public was told to avoid butter but encouraged to eat low-fat yogurt, breakfast cereals, and fruit juice—foods often loaded with sugar or high-fructose corn syrup.
The fat-free revolution was not just a miscalculation.
It was a systematic redirection of science, public policy, and food formulation.
By the end of the 1970s, the foundation was set. Fat had been vilified. Sugar had been exonerated. And fructose—hidden within HFCS and sugary “health” foods—had a clear path into the bloodstream of Americans.


13.3: Fructose Intake and the Heart — A Reassessment Begins

For decades, fructose was framed as a benign sweetener—safe for diabetics, free of glycemic impact, and metabolically inert outside of calorie content. That illusion has collapsed.
Fructose is now understood to be a potent biological signal, not just a source of energy. It triggers endothelial dysfunction, hypertension, inflammation, arrhythmia, myocardial fibrosis, and ultimately, heart failure. These effects are not secondary to obesity or overfeeding. They are primary, direct, and measurable, even in lean individuals.
Fructose does not act alone—but it amplifies every other cardiovascular risk factor, including insulin resistance, hypertension, and lipid dysregulation. It is a metabolic amplifier of heart disease.

Endothelial Dysfunction: The First Step in Atherosclerosis
The endothelium lines every blood vessel in the body. It is not a passive membrane—it is a living, reactive organ, responsible for:
• Vasodilation (via nitric oxide)
• Inflammation regulation
• Thrombosis prevention
• Cholesterol handling

Fructose undermines endothelial function at the molecular level. It bypasses insulin regulation. It is metabolized rapidly in the liver, depleting ATP and generating reactive oxygen species (ROS). These reactive oxygen species degrade nitric oxide (NO), a vasodilator and anti-inflammatory signal. As the local levels of nitric oxide declines, the vessels become stiff, reactive, and inflamed. This endothelial dysfunction is the first step in atherosclerosis.
Fructose also promotes the formation of advanced glycation end-products (AGEs), which further impair vascular elasticity and trigger immune cell adhesion. Macrophages infiltrate, oxidized LDL is engulfed, and foam cells form—the microscopic signature of plaque. Fructose does not simply “raise blood sugar.” It initiates vascular injury at the cellular level.

Evidence Across the Literature
Studies in Circulation Research and JAHA show that high-fructose diets increase vascular inflammation, even without excess calories or weight gain. Fructose-fed animals develop:
• Increased intima-media thickness of the walls of arteries
• Elevated vascular adhesion molecules
• Higher rates of atherosclerotic plaque formation in arteries
These findings are replicated across species and reinforced by human data linking high fructose intake to early arterial stiffening, elevated blood pressure, and increased cardiovascular event risk—even in normal-weight individuals.
Fructose is not “just another sugar.” It is a vascular toxin that accelerates the journey from metabolic stress to cardiovascular disease.


13.4: Fructose, Uric Acid, and Hypertension

Of all the cardiovascular effects of fructose, few are as well documented—and as clinically important—as its role in the development of hypertension. Fructose acts through multiple, converging pathways to raise blood pressure, disrupt renal function, and impair vascular homeostasis.
Unlike sodium, whose hypertensive effects are widely acknowledged, fructose’s role remains under-recognized, despite mounting evidence. It is not merely a dietary excess—it is a biochemical catalyst of high blood pressure.

Mechanisms of Fructose-Induced Hypertension

1. Uric Acid Generation
During hepatic metabolism, fructose drives rapid phosphorylation, which depletes intracellular ATP, thereby elevating AMP, which is degraded to uric acid.
Elevated uric acid leads to endothelial dysfunction (via inhibition of nitric oxide production), vasoconstriction, and renal microvascular injury. These changes collectively increase systemic vascular resistance.

2. Renal Sodium Retention
Fructose impairs renal uric acid excretion and alters tubular sodium handling, leading to vVolume expansion, salt-sensitive hypertension, and activation of sympathetic nervous system outflow

3. Renin–Angiotensin–Aldosterone System (RAAS) Activation
Fructose stimulates RAAS, increasing levels of renin and angiotensin II (a potent vasoconstrictor). Aldosterone (promotes fluid retention and potassium loss). These hormones raise blood pressure, promote vascular hypertrophy, and increase afterload (resistance to forward flow) on the heart. This is particularly dangerous in patients with diastolic dysfunction.
Animal and Human Data
Animal studies in Hypertension and American Journal of Physiology show that even in the absence of weight gain. Fructose-fed rodents develop sustained systolic hypertension. They exhibit arterial stiffness, RAAS activation, and renal oxidative stress.
Human observational data corroborates this. High-fructose intake is associated with higher systolic blood pressure. Uric acid levels predict incident hypertension, even in adolescents. Fructose is not a passive contributor to high blood pressure. It is a primary hypertensive agent, capable of driving vascular damage independently of calories or weight.


13.5: Fructose and Atherosclerotic Plaques

Atherosclerosis is not a passive process of cholesterol deposition. It is an inflammatory, immune-mediated disease that progresses through endothelial dysfunction, lipid infiltration, macrophage activation, and plaque instability.
Fructose accelerates each stage. Emerging evidence suggests that fructose-induced cardiovascular disease is not confined to the bloodstream. It begins, in part, in the gut. Excessive fructose intake alters the intestinal microbiome—promoting gut dysbiosis, increasing intestinal permeability, and allowing endotoxins like lipopolysaccharide (LPS) to enter the circulation. This phenomenon, known as metabolic endotoxemia, stimulates hepatic inflammation and drives the production of C-reactive protein (CRP)—a key inflammatory marker and active participant in atherosclerosis [21,22].
CRP does more than reflect inflammation. It contributes to it. Elevated CRP levels have been strongly associated with increased plaque burden, endothelial dysfunction, and plaque instability in multiple human studies [23].
In this model, fructose initiates a chain of events that begins in the gut and ends in the arterial wall. Dysbiosis, CRP, and atherosclerosis form a tight triangle, one that implicates fructose not just as a liver toxin, but as a vascular risk factor acting through microbial and inflammatory pathways. This adds a new dimension to the cardiovascular consequences of sugar—one that ties together diet, immunity, and heart disease.

From Inflammation to Instability
Fructose activates inflammatory pathways at the molecular level. It increases the expression of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP). These cytokines activate matrix metalloproteinases (MMPs), enzymes that degrade the fibrous cap of atherosclerotic plaques.
When the fibrous cap thins, plaque rupture becomes more likely—leading to thrombosis, myocardial infarction, or stroke. This is not a slow, inert process. It is active vascular instability, driven in part by fructose.

Lipid Oxidation and Macrophage Recruitment
Fructose consumption increases oxidized LDL, macrophage infiltration into the intima and foam cell formation. These macrophages secrete inflammatory mediators that perpetuate the cycle of plaque expansion and destabilization.

Atherogenic Synergy
Fructose rarely acts alone. It coexists with hypertriglyceridemia, insulin resistance and hypertension. All of these factors interact synergistically to accelerate the atherosclerotic process. Fructose doesn’t just add to plaque burden—it creates a plaque phenotype that is unstable, inflamed, and vulnerable to rupture.

Clinical and Experimental Evidence
• Studies in Arteriosclerosis, Thrombosis, and Vascular Biology demonstrate that high-fructose diets increase macrophage activity, oxidized lipid deposition, and plaque vulnerability. Imaging studies show that patients with high fructose intake have greater coronary calcification and intima-media thickness. Fructose is not just a toxin—it is a vascular threat, capable of triggering sudden, life-threatening cardiovascular events.


13.6: Fructose and Heart Failure — HFpEF and the Modern Epidemic

In recent decades, the landscape of heart failure has shifted. Heart failure with preserved ejection fraction (HFpEF) now accounts for over half of all heart failure admissions worldwide. This is not the classic heart failure of the 20th century, caused by infarction and reduced pump strength. This is a new phenotype, defined by diastolic dysfunction, myocardial stiffness, inflammation, not infarction. However they usually have close to a normal ejection fraction on echocardiogram. They often have, metabolic syndrome without overt coronary artery disease. At the center of this evolution is fructose.

Fructose and the Stiff Heart
Fructose promotes visceral fat accumulation, systemic inflammation, and endothelial dysfunction—the same factors that define the HFpEF patient. But more than that, fructose drives direct myocardial remodeling.
Mechanisms of damage include lipotoxicity within cardiomyocytes (fat toxicity inside heart muscle cells), fibroblast activation via transforming growth factor-beta (TGF-β), collagen deposition, leading to myocardial stiffening mitochondrial dysfunction and ATP depletion and increased myocardial filling pressures, even at rest
Patients with HFpEF often report dyspnea on exertion, fatigue, and exercise intolerance. Under stress, their hearts cannot relax fast enough to accommodate increased venous return. Pulmonary pressures rise, and symptoms appear. Fructose is not just involved—it creates the substrate, the trigger, and the fuel for this form of heart failure.

Epicardial Fat and Cardiac Compression
High-fructose diets increase epicardial and pericardial fat, which compresses the myocardium, impairs myocardial relaxation, and secretes pro-inflammatory adipokines directly into the coronary circulation. These fat depots correlate strongly with left atrial enlargement, diastolic dysfunction, and cardiovascular mortality.

Fibrotic Remodeling in Action
Animal studies confirm what imaging and autopsy studies in humans now show. Mice on high-fructose diets develop interstitial fibrosis, collagen cross-linking, and diastolic strain—all while maintaining ejection fraction.
Human studies in Circulation: Heart Failure and JACC reveal the same phenotype in HFpEF patients: fibrotic, stiff, inflamed myocardium without obstructive coronary disease.

The New Face of Heart Failure, Heart Failure with Preserved Ejection Fraction
Patients with HFpEF are often middle-aged or older women. They are frequently obese, hypertensive, and insulin-resistant. They usually have elevated intracardiac filling pressures at rest. With exercise when the heart rate increases, there is further elevation of pressures inside the left atrium which can cause back flow into the lungs causing pulmonary edema and pulmonary venous hypertension manifest as a feeling of smothering, requiring stopping the activity to rest and allow the heart rate to come back down.
This is not a disease of cholesterol. It is a disease of metabolic inflammation and fibrotic remodeling, driven in large part by fructose. HFpEF is not a mystery. It is the predictable outcome of years of fructose exposure, dietary error, and metabolic neglect.
In the interface of obstetrics and cardiology, the combination of obesity and diabetes can cause heart failure problems in pregnancy particularly when the heart rate speeds up in the second half of pregnancy. Hypertension is often


13.7: Pediatric and Early-Onset Cardio-metabolic Heart Disease

Perhaps the most alarming consequence of fructose’s silent rise is that cardiovascular disease is now a pediatric condition. For the first time in history, cardiologists are diagnosing fatty liver, diastolic dysfunction, and even left ventricular hypertrophy in children.

The Early Warning Signs
• Children as young as eight now present with hepatic steatosis, despite no alcohol use.
• Adolescents show elevated blood pressure, hypertriglyceridemia, and insulin resistance
• Imaging studies reveal epicardial fat, impaired myocardial relaxation, and concentric remodeling

These changes do not require decades to appear. They can emerge within months of sustained high-fructose intake—especially from sugar-sweetened beverages (SSBs).

The UCSF Clinical Trial: Reversibility Without Weight Loss
In a landmark 2016 study, Dr. Robert Lustig and colleagues placed obese children on an isocaloric diet that removed added fructose but kept calories constant. In just nine days, without weight loss, participants showed lower triglycerides, improved insulin sensitivity, reduced liver fat and lower blood pressure. This trial confirmed what clinicians had long observed: fructose, not calories alone, drives early metabolic injury.

Sudden Cardiac Death and Obesity Cardiomyopathy
In 2023, a study in JACC: Dr. Joseph Westaby described a new phenotype: “Obesity Cardiomyopathy”. Autopsies of obese adolescents who died suddenly revealed grossly enlarged hearts (>550g in males, >450g in females), no evidence of myocardial infarction, valve disease, or major coronary blockage. However there was evidence of lipid overload, mitochondrial dysfunction, and electrical instability. These deaths, in teens and young adults with no previous cardiac diagnosis, highlight a disturbing reality. Fructose is not just creating sick adults. It is creating sudden cardiac death in children. [10]

Cardiac Dysfunction Without Cholesterol
These obese children often have normal LDL cholesterol, no atherosclerosis, but with visible signs of cardiac stress, ventricular stiffening, and enlarged hearts. They are the first generation exposed to chronic, high-dose fructose from infancy—via juices, processed snacks, and sports drinks, and their hearts are paying the price.


13.8: The Reawakening of Cardiology (2015–2025)

From Cholesterol to Metabolism
For more than half a century, cardiology was guided by a singular doctrine: cholesterol causes heart disease. This hypothesis shaped dietary guidelines, pharmaceutical development, and preventive strategies across the globe. And for a time, it worked.
Statins lowered LDL. Angioplasties saved lives. Saturated fat was reduced. Yet something unexpected happened: cardiovascular disease did not disappear. In fact, heart failure rates climbed, obesity rose, and patients with “perfect” lipid panels were dying from metabolic heart disease.

By the mid-2010s, the disconnect between textbook total cholesterol and LDL cholesterol targets and clinical outcomes became too great to ignore.


The Rise of HFpEF and Metabolic Heart Disease
Cardiologists began to observe a new pattern. Patients with normal LDL and clear coronaries who were fatigued, dyspneic, and intolerant to exercise, with preserved ejection fraction, but evidence of diastolic dysfunction, epicardial fat, and fibrosis.

This was HFpEF, a form of heart failure not caused by infarction, but by fructose-induced metabolic remodeling. It was not a disease of cholesterol—it was a disease of mitochondria, fibroblasts, adipokines, and myocardial stiffness.

Dr. Lustig, Dr. Johnson, and the Clinical Convergence
Between 2009 and 2020, researchers like Dr. Robert Lustig and Dr. Richard Johnson reintroduced the concept of fructose as a cardiotoxin. Their work connected dots between uric acid and endothelial dysfunction, fructose and TGF-β activation, hepatic fat and epicardial compression and visceral obesity and QT interval prolongation. They reframed cardiovascular disease as a metabolic process, not a purely vascular one.

Scientific Reinforcement
Peer-reviewed studies confirmed that each additional sugar-sweetened beverage per day increases cardiovascular mortality by 10%, independent of BMI or calories [9].
Fructose elevates triglycerides, reduces HDL, and promotes small, dense LDL [8].
Fructose impairs baroreceptor sensitivity, alters cardiac conduction, and increases the risk of arrhythmia [6–9]
By 2020, leading centers like UCSF, Harvard, and the Cleveland Clinic had begun integrating fructose metabolism into cardiology CME curricula.
The New Cardiologist’s Toolkit
By 2025, forward-thinking clinicians were screening for:
• Uric acid
• Fasting insulin
• Fatty liver
• Fructose consumption patterns
• Fructose as a potential contributor to cirrhosis in Fontan and other cardio-hepatic situations.
Fructose has finally entered the cardiologist’s lexicon—not as an afterthought, but as a core contributor to modern heart disease.


13.9: Final Summary — From Oversight to Obligation

The modern cardiovascular epidemic was not born in a vacuum. It evolved — shaped by dietary guidelines that vilified fat while downplaying the role of sugar, by industrial reformulations that replaced butter with high-fructose corn syrup (HFCS), and by a clinical culture that prioritized cholesterol metrics over metabolic health. Fructose was not merely a bystander. It was a biochemical engine.

What We Missed
In the 1940s, Dublin and Armstrong linked obesity to early cardiovascular mortality — decades before low-density lipoprotein (LDL) could be routinely measured [1].
Post-war autopsies in Europe revealed significantly less atherosclerosis among famine survivors compared to their well-nourished counterparts [2].

In 1967, a review article titled Dietary Fats, Carbohydrates and Atherosclerotic Vascular Disease was published in The New England Journal of Medicine, later reported to have been funded and influenced by the Sugar Research Foundation [24]. This publication contributed to a prolonged scientific focus on dietary fat as the chief culprit in heart disease, sidelining investigations into the role of sugar.

In the 1970s, British physiologist John Yudkin publicly warned of sugar’s role in cardiovascular disease — warnings that were largely dismissed by mainstream nutrition science at the time [3].

In 1984, HFCS quietly replaced sucrose in many major soft drinks in the United States, without widespread public debate.

In the 1990s, metabolic syndrome and non-alcoholic fatty liver disease (NAFLD) rose in prevalence.

In the 2000s, cases of sudden cardiac death began appearing in young individuals with no apparent coronary blockages and normal cholesterol levels.

In the 2010s, heart failure with preserved ejection fraction (HFpEF) emerged as a major clinical syndrome associated with obesity, hypertension, and diabetes.

Yet even today, the dominant nutritional message to patients remains focused on dietary fat — while fruit juices, sports drinks, and processed snacks continue delivering unchecked loads of fructose to the liver and heart.

The figure below, from Dr. Islam’s 2024 publication in Molecular Medicine, illustrates visceral fat deposition across multiple organs, including the myocardium — underscoring the systemic reach of metabolic dysfunction.

(Islam, M.S., Wei, P., Suzauddula, M. et al. The interplay of factors in metabolic syndrome: understanding its roots and complexity. Mol Med 30, 279 (2024). https://doi.org/10.1186/s10020-024-01019-y. Shared under CC BY 4.0 License.)


What We Now Know
Fructose:
Raises triglycerides and promotes visceral adiposity

Disrupts nitric oxide signalling, contributing to endothelial dysfunction and hypertension

Activates TGF-β signalling, leading to myocardial fibrosis and HFpEF

Reduces capillary density in cardiac tissue, impairing oxygen delivery

Increases the risk of arrhythmias, QT prolongation, and sudden cardiac death

Accelerates myocardial energy failure, even in individuals with normal body weight

Does all of this without stimulating satiety, encouraging chronic overconsumption

What Must Be Done
It is time to recognize added fructose as a primary dietary cardiotoxin. Cardiologists, policymakers, and public health leaders must respond accordingly:

Revise dietary guidelines to treat excess added fructose with the same urgency as trans fats — as a dangerous agent of disease

Mandate clear and quantifiable fructose content labelling on all packaged and processed foods

Prohibit the inclusion of HFCS in hospitals, school meals, and government-subsidized food programs

Expand clinician education to include the cardiovascular consequences of fructose metabolism and overload

Allocate research funding toward metabolic cardiology and nutrition-related heart disease
Consider ethnic genetic vulnerabilities in cardiac patients, particularly where metabolic syndrome is present or suspected.

The era of dietary oversight has passed. A new era of obligation must begin.

For practical diagnostic tools, laboratory markers, ICD-10 coding, and clinical screening guidance, see Chapter 21: For Physicians. For population-level gene variants linked to metabolic and cardiac vulnerability, refer to Appendix K Population Variants.